Celularity Inc (CELU)vsRoyalty Pharma Plc (RPRX)
CELU
Celularity Inc
$1.02
-3.77%
HEALTHCARE · Cap: $28.80M
RPRX
Royalty Pharma Plc
$55.02
-0.76%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 9092% more annual revenue ($2.44B vs $26.55M). RPRX leads profitability with a 33.9% profit margin vs 0.0%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
CELU
Avoid18
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+73.7%
Fair Value
$4.68
Current Price
$1.02
$3.66 discount
Margin of Safety
-59.6%
Fair Value
$34.38
Current Price
$55.02
$20.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -6367.0% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CELU
The strongest argument for CELU centers on Debt/Equity.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : CELU
The primary concerns for CELU are Market Cap, Profit Margin, Piotroski F-Score.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
CELU profiles as a value stock while RPRX is a mature play — different risk/reward profiles.
CELU carries more volatility with a beta of 0.48 — expect wider price swings.
RPRX is growing revenue faster at 11.0% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 18/100), backed by strong 33.9% margins and 11.0% revenue growth. CELU offers better value entry with a 73.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Celularity Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Celularity Inc. is a forward-thinking biotechnology company focused on advancing regenerative medicine through its unique cellular products derived from the placenta. The company is advancing a comprehensive pipeline of innovative immunotherapies designed to provide allogeneic off-the-shelf solutions that enhance treatment effectiveness while reducing complications for cancer and other serious diseases. With a strong management team and strategic partnerships, Celularity aims to address significant unmet medical needs, positioning itself as a key player in the evolving field of advanced therapeutics.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?